Saxenda: Dangerous weight loss drug to hit the market

The American Food and Drug Administration (FDA) recently approved drug giant Novo Nordisk’s “new” weight loss drug Saxenda. However, all the drug makers really did was slap a new, harmless-sounding name on a dangerous drug.

Saxenda has a closet that’s chock full of nasty skeletons. Starting with the fact that it is not a new drug at all. Saxenda is just a new name for an old type 2 diabetes drug called Victoza.

As you may recall, Victoza comes with the kind of nightmarish side effects that are practically guaranteed to keep you up at night. That’s if you even survive the night since topping the list is fatal pancreatitis from infection and bleeding followed by kidney impairment.

Victoza also carries a black box warning about causing thyroid tumours in animal studies.

Suffice to say, Saxenda comes with those very same side effects. But with higher levels of the active ingredients it brings along some serious new ones, including suicidal thoughts, gallbladder disease, and elevated heart rate.

For the FDA to approve a drug this potentially dangerous it must work incredibly well… transforming any Tom, Dick or Fat Harry into an Adonis in mere weeks, right?

Yeah, not so much.

In fact, four out of every 10 users won’t drop a single pound. And when it does “work” the numbers reveal the real story. You could lose perhaps four or five per cent of your body weight. In other words, if you weigh 180 pounds we’re talking about seven to nine pounds at most!

Somehow the risk benefit ratio for Saxenda does not look too good.

Wishing you the best of health,

Dr. Jonathan V. Wright
Editor
Nutrition & Healing
Did you find this information useful?


If you enjoyed this content or found it useful and educational, please share this article with your friends and family.

Sources:

FDA approves weight-management drug Saxenda, published online 23.12.14, fda.gov

Leave a comment

Be part of the conversation by becoming a Premium Member. Click here to learn more about membership.


Leave a Reply

Your email address will not be published. Required fields are marked *